| Name | Title | Contact Details |
|---|
Paradigm is a medical diagnostics company serving physicians and patients worldwide.
Meiogen Biotechnology Corporation is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.